Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.

The Lancet. Oncology - 1 Apr 2024

Browne Iseult M, André Fabrice, Chandarlapaty Sarat, Carey Lisa A, Turner Nicholas C

Abstract excerpt

The growing availability of targeted therapies for patients with advanced oestrogen receptor-positive breast cancer has improved survival, but there remains much to learn about the optimal management of these patients. The PI3K-AKT and mTOR pathways are among the most commonly activated pathways in breast cancer, whose crucial role in the pathogenesis of this tumour type has spurred major efforts to target this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to PIK3CA gene

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Receptors, Estrogen

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 38547898
DOI: 10.1016/S1470-2045(23)00676-9

Genes

PIK3CA
AKT1
CDK4
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.PMID 38547898Read ↗

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.Semantic proximity Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical ChallengesSemantic proximity Read ↗

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trialsSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.Semantic proximity Read ↗

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.Semantic proximity Read ↗

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.Semantic proximity Read ↗

Efficacy of PI3K inhibitors in advanced breast cancer.Semantic proximity Read ↗

Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTORSemantic proximity Read ↗

Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.Semantic proximity Read ↗

Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.Semantic proximity Read ↗

Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.